Drug news
NICE rejects Xofigo for Prostate Cancer - Bayer
Draft guidance issued by the National Institute for Health and Care Excellence (NICE) rejects the use of Xofigo (radium-223 dichloride) from Bayer in patients with Prostate Cancer. Trials showed a 14 month overall survival rate compared to 11.2 months for placebo but no data compared the drug to alternative therapies such as docetaxel in first line or aberaterone in second line therapy. NICE found the drug not cost effective.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.